Alkem Laboratories Limited announced the appointment of Laxmikant Tiwari and Niles Vartak to senior management positions effective October 12, 2026. The appointments aim to bolster the company's operational and supply chain capabilities within the pharmaceutical sector.

The disclosure was made under Regulation 30(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Both executives have been appointed for a term lasting as long as they remain in the employment of the company. No relationships between directors were disclosed in connection with these appointments.

Executive profiles and expertise

Laxmikant Tiwari brings over 27 years of experience in pharmaceutical operations. He holds a Master of Business Administration in Operations Management and a Bachelor's degree in Pharmacy. His background focuses on operational execution within the healthcare industry.

Niles Vartak possesses more than 24 years of experience in supply chain leadership across pharmaceutical, healthcare, and consumer goods sectors. He holds a Master of Business Administration in Finance and a Bachelor's degree in Marine Engineering. His expertise spans complex supply chain management in diverse industries.

Appointment details

The company stated that detailed profiles are available on its official website. These appointments reflect Alkem Laboratories' strategy to reinforce its management team with seasoned professionals in key functional areas.

Alkem Laboratories shares flagged a large-trade signal on NSE, with approximately 50,611 shares changing hands at ₹5,274.00, amounting to a combined value of ₹26.69 crore.

This is a real-time large-trade signal, not a confirmed block or bulk deal. NSE/BSE publish official block and bulk deal reports only after market close — this trade may or may not appear there.

Trade details

The signal was flagged on NSE, reflecting a cluster of trades in Alkem Laboratories shares printed within a short window at or near ₹5,274.00. The combined value of the flagged activity stood at ₹26.69 crore across approximately 50,611 shares. The signal was generated by a real-time trade-scanning system based on size and speed of activity, and is not a confirmation by the exchange of any officially classified event.

The following table summarises the key parameters of the flagged activity:

What this signal means

This activity reflects trade-level data — a cluster of trades in Alkem Laboratories shares printed within a short window at or near the quoted price, for a combined value as stated. No buyer, seller, broker, or client identity is available from this signal; such information is disclosed by the exchange only after market close, if the activity qualifies under exchange-defined criteria.

What this is, and isn't: this reflects trade-level activity — a cluster of trades in the stock above, printed within a short window at or near the quoted price, for a combined value as stated. It is generated by our real-time trade-scanning system and is not, by itself, evidence of a block or bulk deal.

A block deal has to be executed in the exchange's dedicated window (8:45–9:00am or 2:05–2:20pm), within a set price band, and above the current minimum order size (₹25 crore). A bulk deal is when one client's total trading in a stock crosses 0.5% of its equity in a single day — confirmed only once every trade that client made is added up.

Both are published by NSE/BSE after trading hours end, typically after 3:30pm — never before. If this trade qualifies as either, it will appear in the exchange's own report later today, not here first.